

Protalix BioTherapeutics, Inc.  
Form 8-K  
May 29, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): May 29, 2012**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

|  |   |  |
|--|---|--|
| Florida<br><b>(State or other jurisdiction<br/>of incorporation)</b> | 001-33357<br><br>(Commission File Number) | 65-0643773<br><b>(IRS Employer<br/>Identification No.)</b> |
|--|---|--|

|   |                                |
|---|--------------------------------|
| 2 Snunit Street<br>Science Park, POB 455<br>Carmiel, Israel<br>(Address of principal executive offices) | 20100<br><br><b>(Zip Code)</b> |
|---|--------------------------------|

**Registrant's telephone number, including area code +972-4-988-9488**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure**

On May 29, 2012, Protalix BioTherapeutics, Inc. issued a press release announcing that senior management will present at three upcoming conferences. Details regarding the conferences are as follows:

Jefferies 2012 Global Healthcare Conference

Presenter: Mr. Yossi Maimon, Chief Financial Officer

Corporate Presentation

Monday, June 4, 2012 at 1:30 PM EDT

New York, NY

*A webcast of this presentation will be available at [www.protalix.com](http://www.protalix.com) on the event calendar page and a replay will be archived and available after the conference for 30 days.*

2012 BIO International Convention

Presenter: Dr. David Aviezer, President and Chief Executive Officer

Session titled, “Neither Beast nor Bird: Addressing Biomanufacturing Challenges with New Expression Systems.”

Tuesday, June 19, 2012 at 10:00 AM EDT

Room 258B of the Boston Convention & Exhibition Center, MA

Corporate Presentation

Tuesday, June 19, 2012 at 3:45 PM EDT

Room 104A of the Boston Convention & Exhibition Center, MA

Wells Fargo Securities Research & Economics 2012 Healthcare Conference

Presenter: Dr. David Aviezer, President and Chief Executive Officer

Corporate Presentation

Wednesday, June 20, 2012 at 9:30 AM EDT

InterContinental Boston, Boston, MA

*A webcast of this presentation will be available at [www.protalix.com](http://www.protalix.com) on the event calendar page and a replay will be archived and available after the conference for 30 days.*

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

A copy of the press release is furnished as Exhibit 99.1.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits**

(d)

**Exhibits**

99.1

Press release dated May 29, 2012.

3

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX  
BIOTHERAPEUTICS, INC.

Date: May 29, 2012 By: /s/ David Aviezer  
Name: David Aviezer, Ph.D.  
Title: President and  
Chief Executive Officer